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Abstract: Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common
disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings
has been reported to boost the effect of BoNT-A. To date, a wide range of stimulation protocols
has been proposed in the literature. We conducted a systematic review of current literature on the
protocols of electrical stimulation to boost the effect of BoNT-A injection in patients with spasticity. A
systematic search using the MeSH terms “electric stimulation”, “muscle spasticity” and “botulinum
toxins” and strings “electric stimulation [mh] OR electrical stimulation AND muscle spasticity
[mh] OR spasticity AND botulinum toxins [mh] OR botulinum toxin type A” was conducted on
PubMed, Scopus, PEDro and Cochrane library electronic databases. Full-text articles written in
English and published from database inception to March 2021 were included. Data on patient
characteristics, electrical stimulation protocols and outcome measures were collected. This systematic
review provides a complete overview of current literature on the role of electrical stimulation to
boost the effect of BoNT-A injection for spasticity, together with a critical discussion on its rationale
based on the neurobiology of BoNT-A uptake.
Keywords: botulinum toxins; electrical stimulation; muscle spasticity; physical therapy modali-
ties; rehabilitation
Key Contribution: Electrical stimulation may boost the effect of botulinum toxin type A (BoNT-A)
injection in muscles affected by spasticity. Based on BoNT-A uptake neurobiology, we suggest a
single electrical stimulation session lasting 30–60 min applied on the injected muscles immediately
after BoNT-A administration.
1. Introduction
Botulinum neurotoxin type A (BoNT-A) is a single-chain polypeptide of about 150,000 Da
molecular weight produced by Clostridium botulinum [1]. BoNT-A selectively inhibits the
release of acetylcholine (Ach) at peripheral cholinergic nerve endings, causing chemical
denervation due to the cleavage of SNAP-25 protein, a part of the SNARE complex, which
is required for vesicle docking and, consequently, Ach release [2]. The action of BoNT-
A at nerve endings consists of the following four steps: (1) binding, (2) internalization,
(3) translocation and (4) proteolysis [3]. BoNT-A is composed of a heavy chain and a
light chain linked together by a single disulfide bond, with the C-terminal of the heavy
chain mainly responsible for binding; its N-terminal is involved in the membrane translo-
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cation process, while the light chain exerts the intracellular catalytic (metalloprotease)
activity [1–3].
BoNT-A binds with high affinity to the presynaptic cell membrane of skeletal choliner-
gic nerve terminals. This peculiar tropism and catalytic activity, which leads to neuromus-
cular transmission transient blockade, are the basis of the therapeutic use of BoNT-A in
patients with neurological conditions associated with overactive muscle conditions [4]. In
particular, BoNT-A represents a first-line treatment for the management of spasticity [5,6],
which may occur as a consequence of several neurological conditions affecting adults
and children, such as stroke, multiple sclerosis, traumatic brain injury, spinal cord injury,
tumors, neurodegenerative disorders and cerebral palsy [6–8]. The term spasticity refers
to a disordered sensorimotor control, presenting as intermittent or sustained involuntary
involvement of muscles [7]. In addition to BoNT-A, other treatment options for managing
spasticity are oral medications, chemodenervation with phenol or alcohol, intrathecal
baclofen, rehabilitation procedures, physical modalities, and surgical interventions [9,10].
1.1. Issues in the Management of Spasticity with Botulinum Toxin and Rationale to Boost Its Effect
To date, three brands of BoNT-A are approved for treating spasticity in clinical practice:
abobotulinumtoxinA (Dysport, Ipsen, Boulogne-Billancourt, France), incobotulinumtoxinA
(Xeomin, Merz, Frankfurt am Main, Germany) and onabotulinumtoxinA (Botox, Allergan,
Irvine, CA, USA) [5,11]. Their efficacy and safety have been demonstrated for labeled doses,
which may vary across countries according to their own regulations [5]. In real-world
practice, to achieve appropriate clinical and neurorehabilitative goals, the treatment of
multifocal spasticity may require doses of BoNT-A that are higher than the recommended
regimen [12]. Thus, depending on the clinical presentation of spasticity in some patients, the
cumulative and/or per muscle dose of BoNT-A may be higher than that recommended by
the product label [13,14]. Adverse events and antibody development must be considered
as potential risks of high-dose BoNT-A therapy [12]. To date, the safety of BoNT-A
injection regimens at higher than label-recommended doses is supported by growing
evidence [12,15–18], although the theoretical risk of local side effects due to the spreading
of BoNT-A to the adjacent muscles cannot be ruled out [19]. Furthermore, the data
regarding the safety of prolonged use of high BoNT-A doses are limited [12,15,20]. In
this frame, it is worth noting that the development of neutralizing antibodies seems to be
favored by long-duration therapy with high doses and short intervals between treatment
cycle injections, although neutralizing antibodies have been reported in only 1% of subjects
treated with BoNT-A for limb spasticity, without significant difference between brands [21].
Lastly, it is noteworthy that high-dose BoNT-A treatments may be more expensive than
on-label ones [19,22].
Therapeutic strategies to boost the effect of BoNT-A thus seem useful to overcome the
issues described above and may lead to some advantages, such as the injection of lower
BoNT-A dosages, fewer side effects and lower costs.
1.2. Electrical Stimulation as Booster for Botulinum Toxin Effect
To date, several rehabilitation procedures have been proposed as adjuvant treatments
associated with BoNT-A injection for the management of spasticity, including muscle
stretching; taping; casting; splinting; orthoses; and physical modalities such as extracorpo-
real shock wave therapy, therapeutic ultrasound, vibration therapy, electrical stimulation,
and transcutaneous electrical nerve stimulation [23,24].
Rat diaphragm preparation studies conducted in the 1960s suggested a reduction in
latency of the onset of BoNT-A paralytic effect after electrical stimulation of motor nerve
endings [25]. Specifically, electrical stimulation was shown to enhance the neuromuscular
blockade effect of BoNT-A by increasing and accelerating the toxin uptake at the motor
nerve terminals in animal models [25,26]. In particular, electrical stimulation may speed
up the binding/internalization and translocation of BoNT-A, which have half-times of
approximately 12 and 5 min, respectively [26]. Furthermore, studies on cultured neuron
Toxins 2021, 13, 303 3 of 13
models showed not only a quick (i.e., occurring a few minutes after toxin exposure)
internalization of BoNT-A due to endocytosis mediated by high-affinity receptors but also
a protective effect of pH neutralizing substances against BoNT-A intoxication less than
40 min after toxin exposure [1,27].
In the same line, evidence in humans without spasticity suggested an important role
of the injected muscle activity in the clinical response to BoNT-A [28]. In 1995, Hesse and
colleagues were the first to investigate the possibility of enhancing the effect of BoNT-A
by means of electrical stimulation in patients with stroke and spasticity [29]. Since then,
several electrical stimulation protocols have been proposed to boost the effect of BoNT-A in
patients with spasticity. Despite the encouraging evidence reported by many studies, there
is no agreement on several parameters, such as the time of administration after BoNT-A
injection, the stimulation frequency, and the duration of stimulation sessions [19].
To offer a critical update on the state of the art in this still-controversial topic, we have
systematically reviewed the literature on the use of electrical stimulation to boost the effect
of BoNT-A on spastic muscles.
2. Results
We included a total of sixteen articles, whose findings are described below.
2.1. Adult Patients
Nine studies (randomized controlled trial: n = 8, case-control study: n = 1; chronic
stroke patients: n = 8, lower-limb spastic paraparesis: n = 1) were included [29–37]. Four
studies dealt with upper limb spasticity with the following muscles as injection targets:
biceps brachii, flexor carpi radialis, flexor carpi ulnaris, flexor digitorum superficialis,
flexor digitorum profundis and abductor digiti minimi [32,35–37]. Five studies were
conducted on patients with lower limb spasticity and considered the following muscles
as injection targets: gastrocnemius, soleus, tibialis posterior and extensor digitorum
brevis [29–31,33,34]. AbobotulinumtoxinA was used in four studies (upper limb: n = 1,
lower limb: n = 3) [29,33–35]. OnabotulinumtoxinA was used in five studies (upper limb:
n = 3, lower limb: n = 1; both upper and lower limb: n = 1) [30–32,36,37]. Protocols for
electrical stimulation utilized 30–60-min sessions. There was great variability in terms of
session frequency (range: 1–6 times/day), total number (range: 1–18) and duration of the
stimulation cycles (range: 1–6 days). The electrical stimulation of the injected muscles
was started immediately after BoNT-A injection in three studies [30,36,37] and was started
the day after injection in three studies [32,34,35]; three studies generically reported that
BoNT-A injection was followed by electrical stimulation [29,31,33]. One study used sham
stimulation (i.e., electrodes positioned but no stimulation given) [32]. Studies differed in
terms of stimulation protocol parameters and the combination of electrical stimulation
with other post-injection strategies to improve the effect of BoNT-A. Two studies reported
adverse events after treatment. Table 1 includes detailed information on the treatment
protocols and outcomes.
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Table 1. Studies on adult patients.
Article Summary
Hesse et al., 1995 [29]
Design: randomized controlled trial
Sample: 11 chronic stroke patients affected by lower limb spasticity
Groups: BoNT-A vs. BoNT-A + ES
BoNT-A injected: abobotulinumtoxinA
Injected muscle(s): GM, GL, soleus, TP
Total BoNT-A dose injected: up to 2000 U
Stimulation protocol: 30-min sessions delivered 6 times/day for 3 consecutive days after injection
Stimulation parameters: 20 Hz, 0.2 ms, 50–90 mA
Main findings: BoNT-A + ES led to greater improvement in muscle tone, gait speed, stride length,
stance, and swing-symmetry
Side effects reported: one patient suffered from bladder paresis
PEDro score: 4
Hesse et al., 1998 [35]
Design: randomized controlled trial
Sample: 24 chronic stroke patients affected by upper limb spasticity
Groups: BoNT-A + ES vs. BoNT-A vs. placebo + ES vs. placebo
BoNT-A injected: abobotulinumtoxinA
Injected muscle(s): BB, Br, FCR, FCU, FDS, FDP
Total BoNT-A dose injected: 1000 U
Stimulation protocol: 30-min sessions delivered 3 times/day for 3 consecutive days after injection
Stimulation parameters: 20 Hz, 0.2 ms, 50–90 mA
Main findings: patients treated with BoNT-A + ES showed the greatest reduction in spasticity and
facilitation of hand hygiene
Side effects reported: none
PEDro score: 5
Carda et al., 2005 [33]
Design: case-control study
Sample: 65 chronic stroke patients affected by upper limb spasticity
Groups: BoNT-A + taping vs. BoNT-A + ES + splinting
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): FCR, FCU, FDS, FDP
Total BoNT-A dose injected: up to 372 U (mean)
Stimulation protocol: 60-min session, 1 time/day, 5 consecutive days
Stimulation parameters: 50 Hz, 0.3 ms
Main findings: patients treated with BoNT-A + taping achieved a greater reduction in spasticity with
less time required for the treatment
Side effects reported: none
PEDro score: not applicable (estimated as 4)
Frasson et al., 2005 [34]
Design: randomized controlled trial
Sample: 12 adult patients affected by spastic paraparesis due to multiple sclerosis, Strümpell–Lorrain
disease, cerebral palsy and spinal cord injury
Groups: BoNT-A + low-frequency ES vs. BoNT-A + high-frequency ES
BoNT-A injected: abobotulinumtoxinA
Injected muscle(s): extensor digitorum brevis
Total BoNT-A dose injected: 50 U
Stimulation protocol: 30-min session, 1 time/day, 5 consecutive days
Stimulation parameters: 4/25 Hz, 0.2 ms
Main findings: low-frequency stimulation increased the effect of BoNT-A and induced a rapid and
persistent improvement in spasticity
Side effects reported: none
PEDro score: 4
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Article Summary
Bayram et al., 2006 [32]
Design: randomized controlled trial
Sample: 11 chronic stroke patients affected by lower limb spasticity
Groups: BoNT-A + ES vs. BoNT-A + sham ES
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL, soleus, TP
Total BoNT-A dose injected: up to 400 U
Stimulation protocol: 30-min sessions delivered 6 times/day for 3 consecutive days
Stimulation parameters: 20 Hz, 0.2 ms, 50–90 mA
Main findings: no significant between-group difference
Side effects: pain at injection site (n = 4), muscle weakness (n = 2)
PEDro score: 5
Baricich et al., 2008 [30]
Design: randomized controlled trial
Sample: 23 chronic stroke patients affected by lower limb spasticity
Groups: BoNT-A + ES + stretching vs. BoNT-A + taping vs. BoNT-A + stretching
BoNT-A injected: abobotulinumtoxinA
Injected muscle(s): GM, GL
Total BoNT-A dose injected: up to 500 U
Stimulation protocol: 30-min sessions delivered 2 times/day for 5 consecutive days
Stimulation parameters: 5 Hz, intensity adjusted according to the tolerance of patients
Main findings: ES yielded greater reduction in spasticity (short-term follow-up); taping and ES lead to
better improvement in all outcomes (long-term follow-up)
Side effects reported: none
PEDro score: 6
Picelli et al., 2011 [36]
Design: randomized controlled trial
Sample: 24 chronic stroke patients affected by upper limb spasticity
Groups: BoNT-A + immediate ES vs. BoNT-A + delayed ES
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): BB, abductor digiti minimi
Total BoNT-A dose injected: 95 U
Stimulation protocol: a single 60-min session delivered immediately after injection (immediate ES)
followed by 30-min sessions delivered once/day for 3 consecutive days, starting from the day after
injection (delayed ES)
Stimulation parameters: 4 Hz, 0.2 ms, intensity adjusted to elicit muscle contraction
Main findings: immediate ES leads to greater reduction in spasticity and compound muscle action
potential of injected muscles than delayed ES
Side effects reported: none
PEDro score: 5
Santamato et al., 2013
[37]
Design: randomized controlled trial
Sample: 32 chronic stroke patients affected by upper limb spasticity
Groups: BoNT-A + ES vs. BoNT-A + extracorporeal shock-wave therapy
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): FDS
Total BoNT-A dose injected: up to 140 U
Stimulation protocol: 30-min sessions delivered twice/day for 5 consecutive days
Stimulation parameters: 5 Hz, 50–90 mA
Main findings: extracorporeal shock-wave therapy lead to greater improvement of spasticity, spasms
and pain than ES
Side effects reported: none
PEDro score: 6
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Article Summary
Baricich et al., 2019 [31]
Design: randomized controlled trial
Sample: 30 chronic stroke patients affected by lower limb spasticity
Groups: BoNT-A + ES of injected muscle and antagonists vs. BoNT-A + ES of injected muscles only
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL, soleus
Total BoNT-A dose injected: up to 360 U
Stimulation protocol: a single 60-min stimulation of injected muscles delivered immediately after
BoNT-A injection followed by 60-min sessions delivered to antagonist muscles once/day for 5
consecutive days
Stimulation parameters: 4 Hz, 0.2 ms
Main findings: ES of antagonist muscles yields no further clinical benefit
Side effects reported: none
PEDro score: 7
BoNT-A, botulinum toxin type A; ES, electrical stimulation; GM, gastrocnemius medialis; GL, gastrocnemius lateralis; TP, tibialis posterior;
BB, biceps brachii; Br, brachialis; FCR, flexor carpi radialis; FCU, flexor carpi ulnaris; FDS, flexor digitorum superficialis; FDP, flexor
digitorum profundis; PEDro, Physiotherapy Evidence Database.
2.2. Pediatric Patients
We included seven studies (randomized controlled trial: n = 5, case-control study:
n = 2) on children with spastic cerebral palsy [38–44]. Injection targets were hip adductors,
hamstrings, and calf (i.e., gastrocnemius, soleus and tibialis posterior) muscles as well as
upper limb muscles (i.e., biceps brachii, brachioradialis, pronator teres, flexor carpi radialis
and ulnaris, adductor pollicis and flexor pollicis brevis). OnabotulinumtoxinA was used
in all studies. Except for two studies, which used electrical stimulation sessions of 15 and
20 min/session respectively [43,44], the remaining electrical stimulation protocols utilized
30-min sessions, but there was great variability in terms of treatment session frequency
(range: 6 times/day to 1 time/week), total number of sessions (range: 4–60) and duration
of treatment cycles (range: 3 days to 12 weeks). Only two studies reported that electrical
stimulation of the injected muscles occurred on the same day as BoNT-A injection (the time
between injection and electrical stimulation was specified by one paper) [38,44]. Conversely,
the other studies generically reported that BoNT-A injection was followed by electrical
stimulation, except for one study that reported the start of electrical stimulation three weeks
after injection [43]. One study used sham stimulation, but details of sham stimulation were
not reported [42]. Studies differed in terms of stimulation protocol parameters and the
combination of electrical stimulation with other post-injection strategies to improve the
effect of BoNT-A. None of the studies reported adverse events after treatment. Table 2
includes detailed information on the treatment protocols and outcomes.
Table 2. Studies on pediatric patients.
Article Summary
Detrembleur et al., 2002 [38]
Design: randomized controlled trial
Sample: 12 patients with cerebral palsy affected by lower limb spasticity
Groups: BoNT-A + ES vs. BoNT-A
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL, soleus
Total BoNT-A dose injected: up to 17.5 U/Kg
Stimulation protocol: 30-min sessions delivered 6 times/day for 3 consecutive days, starting on the
day of BoNT-A injection
Stimulation parameters: 20 Hz, 0.2 ms, 50–90 mA
Main findings: combined BoNT-A + ES treatment not superior to BoNT-A
Side effects reported: none
PEDro score: 5
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Article Summary
Kang et al., 2007 [40]
Design: case-control study
Sample: 18 patients with cerebral palsy affected by lower limb spasticity
Groups: BoNT-A + ES + rehabilitation vs. BoNT-A + rehabilitation
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL, soleus
Total BoNT-A dose injected: up to 9.2 U/Kg
Stimulation protocol: 30-min sessions delivered twice/week for 2 consecutive weeks
Stimulation parameters: 40 Hz, 0.3 ms, 10–25 mA
Main findings: ES after BoNT-A injection improved ankle range of motion and gait
Side effects reported: none
PEDro score: not applicable (estimated as 5)
Rha et al., 2008 [42]
Design: case-control study
Sample: 23 patients with cerebral palsy affected by lower limb spasticity
Groups: BoNT-A + high-frequency ES vs. BoNT-A + low-frequency ES vs. sham ES
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL
Total BoNT-A dose injected: up to 5 U/Kg
Stimulation protocol: 30-min sessions, delivered once/day for 7 consecutive days
Stimulation parameters: 4/25 Hz, 0.25 ms
Main findings: compound muscle action potential reduced by both low- and high-frequency ES, but
no significant clinical advantage to ES vs. sham ES
Side effects reported: none
PEDro score: not applicable (estimated as 5)
Mudge et al., 2015 [41]
Design: randomized controlled trial
Sample: 6 patients with cerebral palsy affected by lower limb spasticity
Groups: BoNT-A + ES + stretching vs. BoNT-A + stretching
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): hamstrings
Total BoNT-A dose injected: not reported
Stimulation protocol: 30-min sessions delivered 5 times/week for 12 consecutive weeks
Stimulation parameters: 50 Hz, 0.26 ms
Main findings: no difference in passive extensibility of the hamstring
Side effects reported: none
PEDro score: 5
Elnaggar et al., 2019 [39]
Design: randomized controlled trial
Sample: 60 patients with cerebral palsy affected by lower limb spasticity
Groups: ES + rehabilitation vs. BoNT-A + rehabilitation vs. BoNT-A + ES + rehabilitation
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL, soleus
Total BoNT-A dose injected: up to 12 U/Kg
Stimulation protocol: 30-min sessions delivered 3 times/week for 12 consecutive weeks
Stimulation parameters: 30 Hz, 0.25 ms
Main findings: the integration of ES and BoNT-A influenced ankle biomechanics and postural
stability features
Side effects reported: none
PEDro score: 6
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Table 2. Cont.
Article Summary
Yiğitoğlu et al., 2019 [43]
Design: randomized controlled trial
Sample: 40 patients with diplegic cerebral palsy
Groups: BoNT-A + ES vs. BoNT-A
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): GM, GL, soleus
Total BoNT-A dose injected: up to 10 U/Kg
Stimulation protocol: 20-min sessions delivered 1 time/day for 10 consecutive days
Stimulation parameters: 40 Hz, 0.35 ms
Main findings: both groups benefited from the treatment (no additional benefit of ES on BoNT-A
was found)
Side effects reported: none
PEDro score: 5
Elnaggar et al., 2020 [44]
Design: randomized controlled trial
Sample: 64 patients with cerebral palsy affected by spastic hemiplegia
Groups: BoNT-A + rehabilitation vs. ES + rehabilitation vs. BoNT-A + ES + rehabilitation vs.
rehabilitation
BoNT-A injected: onabotulinumtoxinA
Injected muscle(s): FCU, pronator teres, adductor pollicis, FCR, FPB, brachioradialis, biceps brachii
Total BoNT-A dose injected: up to 12 U/Kg
Stimulation protocol: 15-min sessions delivered 1 time/week for 12 consecutive weeks
Stimulation parameters: 30 Hz, 0.30 ms
Main findings: patients who received BoNT-A + ES + rehabilitation achieved greater improvement
after treatment and a follow-up evaluation
Side effects reported: none
PEDro score: not applicable (estimated as 8)
BoNT-A, botulinum toxin type A; ES, electrical stimulation; GM, gastrocnemius medialis; GL, gastrocnemius lateralis; FCU, flexor carpi
ulnaris; FCR, flexor carpi radialis; FPB, flexor pollicis brevis; PEDro, Physiotherapy Evidence Database.
3. Discussion
Therapeutic electrical stimulation is widely used in neurorehabilitation for strengthen-
ing muscles and improving motor recovery [45]. Furthermore, electrical stimulation has
been reported to reduce spasticity “per se”, although the mechanism remains uncertain,
and the clinical evidence is equivocal [46].
Electrical stimulation has been frequently used as an adjunct treatment to boost the
effect of BoNT-A based on the idea that it might increase its uptake in muscles affected by
spasticity both in adults and children [23]. When considering that BoNT-A uptake takes
place a few minutes after BoNT-A injection [1,25–28], electrical stimulation of the injected
muscle should be delivered early after BoNT-A injection, and the duration and number of
stimulation sessions should be based on the toxin uptake time course [1,27].
The output of this systematic analysis of the literature shows that a wide range of
electrical stimulation protocols have been proposed to boost the effect of BoNT-A in spas-
ticity [29–42], but only a few were designed considering the timing of toxin uptake. In
particular, only four reports clearly specified that electrical stimulation was delivered
immediately after BoNT-A injection (i.e., during toxin uptake) [30,36,37,43]. Three stud-
ies reported that electrical stimulation started the day after BoNT-A injection (i.e., at a
time when toxin uptake is unlikely to be still in progress) [32,34,35]. One study specified
that electrical stimulation started three weeks after BoNT-A injection [44]. Notably, the
remaining eight studies did not specify the exact stimulation timing after BoNT-A treat-
ment [29,31,33,38–42], even if it is likely that electrical stimulation was administered early
after BoNT-A injection in most of them.
The duration of each stimulation session is in line with the timing of BoNT-A uptake
(30–60 min) in all studies, except for two reports that applied stimulation for 15 and
20 min/session, respectively [43,44]. However, several stimulation sessions (i.e., up to 60)
over hours/days, in treatment cycles lasting up to 12 weeks, were applied in many studies.
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The timing of BoNT-A uptake is relatively short and not prolonged or repeated over time.
Thus, the application of multiple stimulation sessions applied on the same day and/or
over long periods of time does not seem to have a robust neurobiological foundation [1,27].
Interestingly, despite the large variability in stimulation protocols and their poor
adherence to the BoNT-A uptake timing, most included studies reported significant ef-
fects on clinical and neurophysiological outcomes in response to electrical stimulation in
combination with BoNT-A injection in comparison to control conditions [29–42,44]. We
speculate that this boosting effect of electrical stimulation on BoNT-A treatment may be
due to the first stimulation session, presumably delivered early after toxin administration
in most studies (see above). The benefits achieved in patients managed with delayed
administration of electrical stimulation or longer stimulation protocols may be related to
the unspecific effect of electrical stimulation to reduce spasticity “per se” rather than to
a specific boosting effect of electrical stimulation on BoNT-A injection. Furthermore, the
effect of other adjuvant treatments (e.g., stretching, splinting, physical therapy) combined
with BoNT-A injection and electrical stimulation might have accounted for the findings
reported in some of the included studies.
Of note, only two papers reported some mild adverse events after electrical stimulation
following BoNT-A injection [29,32], supporting the overall safety of electrical stimulation
protocols for adult and pediatric patients with spasticity.
Our observations are in line with a previous systematic review by Intiso and col-
leagues, which concluded that electrical stimulation may boost BoNT-A injection action
and reduce adult spasticity [19]. Nevertheless, due to the variability in protocols and the
paucity of high-quality trials, the authors did not recommend the combination of BoNT-A
injection and electrical stimulation in clinical practice [19]. Our review is methodologically
different, because we focused on the use of neuromuscular stimulation of the injected mus-
cles to boost the effect of BoNT-A on spasticity in adults and children, and we included all
study types. On the other hand, Intiso and colleagues included only randomized controlled
trials involving adult patients and considered all the types of stimulation (i.e., neuromus-
cular stimulation, transcutaneous electrical nerve stimulation and functional electrical
stimulation), further increasing the variability in protocols and reducing the possibility
of strong conclusions [19]. Another systematic review by Mathevon and colleagues did
not recommend electrical stimulation as an adjunct therapy to BoNT-A injection [47]. In
our view, this conclusion is very limited considering that the authors included only four
studies, i.e., two on functional electrical stimulation and two on neuromuscular stimulation,
in children with spastic cerebral palsy [47].
4. Conclusions
Electrical stimulation may boost the effect of BoNT-A, as suggested by most studies
evaluated in this review. The hypothesized mechanism of action of electrical stimulation
is the enhancement of the BoNT-A uptake process at the presynaptic cholinergic nerve
terminals [1,25,26,28]. Thus, from a neurobiological perspective, electrical stimulation
should be applied to the injected muscles during the BoNT-A uptake process, which occurs
rapidly after injection, to exert a boosting effect in patients with spasticity [1,25,27]. In this
line, from a practical point of view, a single electrical stimulation session performed on the
same day of BoNT-A injection would be preferable, in that it would facilitate the access to
care for patients by reducing the number of visits to hospitals and rehabilitation centers,
as well as reducing the burden of caregivers [48]. Unfortunately, most of the studies
evaluated in this review adopted longer stimulation protocols; thus, it is not possible
to verify whether a single stimulation session lasting 30–60 min applied on the injected
muscles immediately after BoNT-A administration might be sufficient to boost the effect of
BoNT-A in the treatment of spasticity [26,27]. Furthermore, a “per se” antispastic effect
of electrical stimulation should be considered [19,46]. From this perspective, the eventual
contribution of electrical stimulation itself in alleviating spasticity represents an under-
investigated issue, as well as a limit for the relevance of any potentially specific effects on
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BoNT-A injection for spasticity. Thus, there is a need to clearly demonstrate that the effect
of electrical stimulation combined with BoNT-A is more than additive.
Despite the amount of literature about the use of electrical stimulation to boost the
effect of BoNT-A on spasticity, some questions remain open. Do all the injected muscles
have to be stimulated to improve a specific pattern of spasticity? Which part of the muscle
is the one best suited for stimulation? What is the difference in effect after electrical
stimulation of the injected muscles compared to electrical stimulation of the supplying
nerve? What is the most appropriate sham stimulation procedure for the control group?
Some additional issues come from neurophysiological considerations. First, the sus-
tained spontaneous motor unit activity of spastic muscle causes high intrinsic Ach exocy-
tosis and recycling activity favorable to BoNT-A uptake. In such a context, it is unclear
whether the stimulation frequency applied to injected muscle may add to the baseline
motor nerve discharge frequency of spastic muscles. Future studies incorporating moni-
toring of the discharge frequency in motor nerves will help to answer this question [49].
Second, the link between muscle stimulation and the activity of motor neuron terminals,
where the exo/endocytosis activity responsible for BoNT-A uptake takes place, is unclear.
Electrical stimulation of the injected muscle at the frequency used in the studies we have
reviewed may induce muscle contraction but may not be able to stimulate motor nerves or
motor-nerve terminals. Third, muscle contraction secondary to electrical stimulation does
not seem to alter the diffusion pattern or bolus distribution of BoNT [50]. Fourth, BoNT-
induced muscle atrophy might paradoxically reduce the effect of Ach release inhibition
secondary to BoNT injection. From this perspective, prolonged electrical stimulation of the
muscle could prevent muscle fiber atrophy, thus increasing the effect of BoNT. Fifth, muscle
stimulation may retroact on the presynaptic endings and interfere with proprioceptive
information and sensory–motor integration. Because of these lines of reasoning, electrical
stimulation during several days might also modulate the effect of BoNT-A injection in
spastic muscles.
Because of the wide range of protocols proposed in the literature and their limitations
(e.g., the stimulation strength has not been reported in many studies), together with the
great variability in the outcome measures, and considering that the majority of studies
included in this review have a small sample size, with a consequent lack of power, we en-
courage the conduction of further adequately powered multicenter randomized controlled
trials to further support the role of electrical stimulation in improving the effect of BoNT-A
on spasticity and define the most appropriate treatment schedule. In particular, we are not
aware of any relevant in vivo study that explored the most appropriate dose and/or the
dose–response relationship of electrical stimulation. These issues should be also addressed
by future studies.
5. Materials and Methods
A systematic review using the MeSH terms “botulinum toxins”, “electric stimulation”,
“muscle spasticity”, “physical therapy modalities” and “rehabilitation” and strings “electric
stimulation [mh] OR electrical stimulation AND muscle spasticity [mh] OR spasticity AND
botulinum toxins [mh] OR botulinum toxin type A” was conducted on PubMed, Scopus,
PEDro and Cochrane Library electronic databases. The results were limited to original
articles focusing on the use of electrical stimulation of injected muscles to boost the effect of
BoNT-A therapy in adult patients and children suffering from spasticity. Thus, we excluded
papers on animal models and humans without spasticity, as well as studies about the use
of electrical stimulation for spasticity not associated with BoNT-A injection (e.g., functional
electrical stimulation). Full-text articles written in English and published from database
inception to March 2021 were included. Data on patient characteristics, treatment protocols
and outcome measures were collected. Quality was assessed with the PEDro score.
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